Cheng Liao
7PUBLICATIONS
26CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (7)
Sort by Publication Date:
|Oct 30, 2025
HRA00129-C004, a Novel c-Met Antibody-Drug Conjugate, Exerts Encouraging Antitumor Activities and Favorable Safety Profiles.Yunan Tian, Jieqiong Zhang, Xing Sun
|Oct 01, 2025
SDP-LIV1, a Novel and Optimized LIV-1 Antibody-Drug Conjugate Demonstrating Superior Antitumor Efficacy and a Favorable Safety Profile for the Treatment of Solid Tumors.Yani Peng, Changyong Yang, Liwei Dong
|Aug 26, 2025
SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile.Li-Min Wang, Changyong Yang, Xing Sun
|Mar 20, 2025
Development of a Tumor-Specific Multivalent CD40 Agonist Antibody FAPxCD40 for Cancer Therapy: Balancing Efficacy and Toxicity.Simeng Chen, Yuan Lin, Dan Li
|Jan 24, 2025
Co-blocking TIGIT and PVRIG Using a Novel Bispecific Antibody Enhances Antitumor Immunity.Yuan Lin, Kan Lin, Qiang Fu
|Nov 15, 2024
SHR-1806, a robust OX40 agonist to promote T cell-mediated antitumor immunity.Jun Zhang, Lei Zhou, Xing Sun
Pageof 2
